PrairieView Partners’s Viking Therapeutics VKTX Stock Holding History

PrairieView Partners’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-29	Closed	–	–	378
2020 Q4	$0	Buy	+29	New	+$176	﹤0.01%	326

Other funds holding VKTX

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PrairieView Partners's VKTX Position: Q1 2021 in Review

PrairieView Partners sold out of Viking Therapeutics (VKTX) in Q1 2021, closing a stake of 29 shares.

PrairieView Partners first reported a position in VKTX in Q4 2020 and held it in 1 quarter. The position peaked at $0 in Q4 2020. 144 funds tracked by Wall St. Rank hold VKTX as of Q1 2021.

PrairieView Partners reported no remaining Viking Therapeutics position as of Q1 2021 after selling out during the quarter.
PrairieView Partners sold 29 Viking Therapeutics shares in Q1 2021.
PrairieView Partners first reported a position in Viking Therapeutics in Q4 2020 and held it in 1 quarter.
PrairieView Partners's Viking Therapeutics position peaked at $0 in Q4 2020.
144 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2021.

Based on PrairieView Partners's 13F filing for Q1 2021, filed 21 Apr 2021.